Search Results - Clara Armengol Tubau

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study by Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger

Connect to this object online.